medical endoscopy device News
-
Stockholders Approve Delisting from the Official List
BOSTON and SYDNEY — 22 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces that it held its Special Meeting of Stockholders on 21 June 2020 and, in accordance with ASX Listing Rule 3.13.2, is pleased to confirm that each of the ...
-
Placement of $750,000 Unsecured Convertible Promissory Note & Update on Potential Financing and Special Meeting
BOSTON and SYDNEY — 19 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has issued a US$750,000 Unsecured Convertible Promissory Note to Crystal Amber Fund Limited (“Crystal Amber”), the ...
-
Further Extension of Maturity Date of June 2017 Note and Financing Update
BOSTON and SYDNEY — 1 July 2020 — GI Dynamics® Inc. (ASX:GID) (”the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding the extension of the maturity date of the Senior Secured Convertible Promissory Note issued to Crystal Amber Fund Limited (“Crystal ...
-
Further Delisting Update
BOSTON and SYDNEY — 15 July 2020 — GI Dynamics® Inc. (ASX:GID) (the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding the removal of the Company from the Official List of the Australian Securities Exchange (“ASX”) (“Official List”). ...
-
Conversion of June 2017 Convertible Note
BOSTON and SYDNEY — 15 July 2020 — GI Dynamics® Inc. (ASX:GID) (the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, advises that it has received a notice of conversion from Crystal Amber Fund Limited (“Crystal Amber”) (a Related Party for Australian Securities Exchange ...
-
GI Dynamics Completes Initial Closing of a $10 Million Series A Preferred Stock Financing from Crystal Amber
BOSTON — September 10, 2020 — GI Dynamics® Inc. (‘GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the initial closing of its private placement offering of Series A Preferred Stock led by Crystal Amber Fund Limited (“Crystal Amber”), ...
-
GI Dynamics Appoints New Chief Executive Officer and Board of Directors
BOSTON — November 5, 2020 — GI Dynamics® Inc. (“GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, has appointed Joseph Virgilio as president and chief executive officer of GI Dynamics, Mark Lerdal as chairman of the Board of Directors (“the Board”) and ...
-
MedTech Innovator Announces Finalists for $500K 8th Annual Industry Accelerator Competition
MedTech Innovator, the largest accelerator of medical devices in the world, today announced the finalists for MedTech Innovator’s eighth annual competition: Cellvie, Circadia Health, Lief Therapeutics, Moray Medical, and Rhaeos. Virtual attendees of The MedTech Conference, the largest gathering of medtech industry leaders in North America, powered by AdvaMed, will vote online to choose the ...
-
Scivita Medical Raises Nearly RMB0.4 Billion in Series a Funding Round and Strives to Build a World-leading Platform for Innovative Products in Endoscope and Related Fields
Scivita Medical Technology Co., Ltd. ('Scivita Medical*) today announced that it has raised nearly RMB0.4 Billion in Series A funding round, which has become one of the highest financing projects in the field of endoscope in China in recent years. The investment was jointly led by GL Ventures and Lilly Asia Ventures with contribution from Matrix Partners China, Medtronic, Chengwei Capital and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you